<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03148457</url>
  </required_header>
  <id_info>
    <org_study_id>2017-00588</org_study_id>
    <nct_id>NCT03148457</nct_id>
  </id_info>
  <brief_title>Early Versus Late Initiation of Direct Oral Anticoagulants in Post-ischaemic Stroke Patients With Atrial fibrillatioN (ELAN): an International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial</brief_title>
  <acronym>ELAN</acronym>
  <official_title>Early Versus Late Initiation of Direct Oral Anticoagulants in Post-ischaemic Stroke Patients With Atrial fibrillatioN (ELAN): an International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      When to start anticoagulation in patients with an acute ischaemic stroke and atrial
      fibrillation (AF) is a relevant unanswered question in clinical practice. Direct oral
      anticoagulants (DOACs) are highly effective for secondary stroke prevention in these
      patients, but DOACs were never initiated &lt;7 days after stroke onset in recent trials. The
      ELAN trial will determine the net benefit of early versus late initiation of DOACs in
      patients with acute ischaemic stroke related to AF.

      The main objective is to estimate the net benefit of early versus late initiation of DOACs in
      patients with acute ischaemic stroke related to AF.

      The secondary objectives are to assess all vascular events and all-cause mortality after
      early initiation of DOACs in patients with acute ischaemic stroke related to AF compared to
      late initiation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background Atrial fibrillation (AF) is the most common cardiac arrhythmia increasing the risk
      of stroke and systemic thromboembolism and thus mortality and morbidity. Anticoagulation
      therapy, such as with vitamin K antagonists effectively prevents strokes in patients with AF,
      however, increases bleeding complications leading to symptomatic intracerebral haemorrhage.
      Direct oral anticoagulants (DOACs) are at least as effective as vitamin K antagonists in
      preventing recurrent strokes, but with lower rates of symptomatic intracerebral haemorrhage.
      Therefore, these new agents are potentially ideal drugs to treat patients with ischaemic
      stroke related to AF. However, in previous trials comparing DOACs with vitamin K antagonists,
      therapy was initiated later than 7-14 days after onset of ischaemic stroke. Whether, earlier
      initiation of DOACs may prevent recurrent stroke without increasing the risk of symptomatic
      intracerebral haemorrhage remains to be determined.

      Objectives The main objective is to estimate the net benefit of early versus late initiation
      of DOACs in patients with acute ischaemic stroke related to AF.

      The secondary objectives are to assess all vascular events and all-cause mortality after
      early initiation of DOACs in patients with acute ischaemic stroke related to AF compared to
      late initiation.

      Methods All patients of 18 years or older with an acute ischaemic stroke related to AF should
      be screened for this trial.

      Patients in the experimental arm (early treatment) and the control arm (late treatment) will
      receive direct oral anticoagulants for prevention of stroke and systemic embolism in patients
      with AF. Depending on the size of the infarction, early treatment will be started within 48
      hours after symptom onset (minor and moderate ischaemic stroke) or at day 6 + 1 day after
      symptom onset (major ischaemic stroke). Patients in the control arm will receive late
      treatment as per current recommendations (i.e. minor ischaemic stroke after day 3 + 1 day,
      moderate ischaemic stroke after day 6 + 1 day and major ischaemic stroke after day 12 + 2
      day).

      The primary outcome is a composite of major bleeding, recurrent ischaemic stroke, systemic
      embolism and/or vascular death at 30 ± 3 days after randomisation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 6, 2017</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of major bleeding, recurrent ischaemic stroke, systemic embolism and/or vascular death</measure>
    <time_frame>30 ± 3 days after randomisation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale (mRS)</measure>
    <time_frame>30 days, 90 days after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>30 days, 90 days after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-major bleeding</measure>
    <time_frame>30 days, 90 days after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of stroke</measure>
    <time_frame>30 days, 90 days after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic embolism</measure>
    <time_frame>30 days, 90 days after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular death</measure>
    <time_frame>30 days, 90 days after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>90 days after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>90 days after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major cardiovascular events defined as composite of stroke, myocardial infarct, heart failure or cardiovascular death</measure>
    <time_frame>90 days after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Silent brain lesions</measure>
    <time_frame>90 days after randomisation</time_frame>
    <description>If CT/MRI is performed in clinical routine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Favourable outcome defined as mRS ≤ 2 and shift analysis adjusted to premorbid mRS</measure>
    <time_frame>90 days after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIHSS</measure>
    <time_frame>90 days after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transient ischemic attack</measure>
    <time_frame>30 days, 90 days after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Undetermined stroke</measure>
    <time_frame>30 days, 90 days after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance</measure>
    <time_frame>30 days after randomisation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Ischaemic Stroke</condition>
  <arm_group>
    <arm_group_label>Early treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Early treatment of patients with ischaemic stroke related to atrial fibrillation (AF) with direct oral anticoagulations (DOACs).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Late treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment with direct oral anticoagulations (DOACs) according the current standard practice in patients with acute ischemic stroke related to atrial fibrillation (AF).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Early treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®)</intervention_name>
    <description>Early treatment will be started within 48 hours after symptom onset (minor and moderate ischaemic stroke) or at day 6 + 1 day after symptom onset (major ischaemic stroke)</description>
    <arm_group_label>Early treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Late treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®)</intervention_name>
    <description>Patients in the control arm will receive late treatment as per current recommendations (i.e. minor ischaemic stroke after day 3 + 1 day, moderate ischaemic stroke after day 6 + 1 day and major ischaemic stroke after day 12 + 2 day).</description>
    <arm_group_label>Late treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent according to country specific details

          -  Age: ≥18 years

          -  Acute ischemic stroke, either confirmed by MRI or CT scan (tissue based definition) or
             by sudden focal neurological deficit of presumed ischaemic origin that persisted
             beyond 24 hours and otherwise normal non-contrast CT scan. Please note: prior
             intravenous or endovascular treatment is allowed.

          -  Permanent, persistent, or paroxysmal spontaneous AF previously known or diagnosed
             during the index hospitalization

          -  Agreement of treating physician to prescribe DOACs

        Exclusion Criteria:

          -  Atrial fibrillation due to reversible causes (e.g. thyrotoxicosis, pericarditis,
             recent surgery, myocardial infarct)

          -  Valvular disease requiring surgery

          -  Mechanical heart valve(s)

          -  Moderate or severe mitral stenosis. Please note that other valvular diseases and
             biological valves are eligible

          -  AF and conditions other than AF that require anticoagulation, including therapeutical
             dose of low-molecular-weight heparin or heparin. Please note: infratherapeutic
             anticoagulation at ischaemic stroke onset defined as follows is not an exclusion
             criteria:

               -  Vitamine K antagonist: International Normalized Ratio (INR) &lt;1.7

               -  Anti-IIa: thrombin time &lt;80 seconds and/or anti-IIa &lt;50 ng/ml

               -  Anti-Xa: anti-Xa &lt;50 ng/ml

          -  Subject who is contraindicated to DOACs

          -  Female who is pregnant or lactating or has a positive pregnancy test at time of
             admission

          -  Patients with serious bleeding in the last 6 months or is at high risk of bleeding
             (e.g. active peptic ulcer disease, platelet count &lt; 100'000/mm3 or haemoglobin &lt; 10
             g/dl or INR ≥ 1.7, documented haemorrhagic tendencies or blood dyscrasias)

          -  Subject currently uses or has a recent history of illicit drug(s) or abuses alcohol
             (defined as regular or daily consumption of more than four alcoholic drinks per day)

          -  Severe comorbid condition with life expectancy &lt; 6 months

          -  Severe or moderate renal insufficiency as defined by creatinine clearance &lt; 50 ml/min

          -  Subject who requires haemodialysis or peritoneal dialysis

          -  Subject with aortic dissection

          -  Current participation in another investigational trial

          -  Dual antiplatelet therapy at baseline or strong likelihood to be treated with dual
             antiplatelet therapy during the course of the trial

          -  CT or MRI evidence of haemorrhage classified as PH1 (defined as parenchymal
             haemorrhage = blood clots in &lt;30% of the infarcted area without or with slight
             space-occupying effect) and PH2 (defined as blood clots in &gt;30% of the infarcted area
             with a substantial space-occupying effect) independently of clinical deterioration.
             Please note that HI1 (defined as haemorrhagic infarct = small petechiae along the
             margins of the infarct) and HI2 (defined as confluent petechiae within the infarcted
             area but no space occupying effect) are acceptable if not associated with clinical
             deterioration and if the treating physician feels comfortable to treat patients with
             DOACs.

          -  CT or MRI evidence of mass effect or intra-cranial tumour (except small meningioma)

          -  CT or MRI evidence of cerebral vasculitis

          -  Endocarditis

          -  Evidence of severe cerebral amyloid angiopathy if MRI scan performed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Urs Fischer, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Neurology, Inselspital Bern</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Miriam Paulisch, PhD</last_name>
    <phone>+41 31 632 67 80</phone>
    <email>miriamhelen.paulisch@insel.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stefanie Lerch, PhD</last_name>
    <phone>+41 31 632 73 09</phone>
    <email>stefanie.lerch@insel.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rita Lachmund</last_name>
    </contact>
    <investigator>
      <last_name>Dominik Michalski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuela Plischke</last_name>
    </contact>
    <investigator>
      <last_name>Bernd Kallmünzer, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dagmar Otto</last_name>
    </contact>
    <investigator>
      <last_name>Götz Thomalla, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Medicine, University of Thessaly</name>
      <address>
        <city>Larissa</city>
        <state>Thessaly</state>
        <zip>41110</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>George Ntaios, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Neurology, Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <state>Aargau</state>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Krassen Nedeltchev, Prof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Neurology, Universitätsspital Basel</name>
      <address>
        <city>Basel</city>
        <state>Basel Stadt</state>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Leo Bonati, Prof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Neurology, Kantonsspital Chur</name>
      <address>
        <city>Chur</city>
        <state>Graubünden</state>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sylvan Albert, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Neurology, Kantonsspital Lugano</name>
      <address>
        <city>Lugano</city>
        <state>Tessin</state>
        <zip>6900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Carlo Cereda, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Neurology, Universitätsspital Lausanne</name>
      <address>
        <city>Lausanne</city>
        <state>Waadt</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Patrik Michel, Prof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Neurology, Hôpital de Zone de Nyon</name>
      <address>
        <city>Nyon</city>
        <state>Waadt</state>
        <zip>1260</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Julian Niederhäuser, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Neurology, Kantonsspital Sion</name>
      <address>
        <city>Sion</city>
        <state>Wallis</state>
        <zip>1951</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christophe Bovin, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Neurology, Bern University Hospital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miriam Paulisch, Dr. phil. nat.</last_name>
      <phone>+41 31 632 67 80</phone>
      <email>miriamhelen.paulisch@insel.ch</email>
    </contact>
    <investigator>
      <last_name>Urs Fischer, Prof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Neurology, Kantonsspital Fribourg</name>
      <address>
        <city>Fribourg</city>
        <zip>1708</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andrea Humm, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Neurology, Universitätsspital Genf</name>
      <address>
        <city>Geneve</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Fabienne Perren, Prof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Neurology, Kantonsspital Luzern</name>
      <address>
        <city>Luzern</city>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Martin Müller, Prof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Neurology, Kantonsspital St.Gallen</name>
      <address>
        <city>St.Gallen</city>
        <zip>9000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jochen Vehoff, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Neurology, Universitätsspital Zürich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christoph Globas, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Greece</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2017</study_first_submitted>
  <study_first_submitted_qc>May 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2017</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stroke</keyword>
  <keyword>Direct oral anticoagulation</keyword>
  <keyword>Apixaban</keyword>
  <keyword>Dabigatran</keyword>
  <keyword>Rivaroxaban</keyword>
  <keyword>Edoxaban</keyword>
  <keyword>Therapy initiation</keyword>
  <keyword>Major bleeding</keyword>
  <keyword>Atrial fibrillation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Apixaban</mesh_term>
    <mesh_term>Edoxaban</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

